Capital Advisors Inc. OK Sells 140,045 Shares of Tilray Brands, Inc. $TLRY

Capital Advisors Inc. OK lessened its holdings in Tilray Brands, Inc. (NASDAQ:TLRY) by 93.3% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 10,005 shares of the company’s stock after selling 140,045 shares during the period. Capital Advisors Inc. OK’s holdings in Tilray Brands were worth $90,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Tidal Investments LLC boosted its stake in shares of Tilray Brands by 15.0% in the second quarter. Tidal Investments LLC now owns 28,971,835 shares of the company’s stock worth $12,006,000 after acquiring an additional 3,776,410 shares during the period. Millennium Management LLC raised its stake in Tilray Brands by 281.0% during the 3rd quarter. Millennium Management LLC now owns 4,942,319 shares of the company’s stock valued at $8,550,000 after purchasing an additional 3,645,060 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Tilray Brands in the 3rd quarter worth approximately $5,813,000. Ausdal Financial Partners Inc. purchased a new position in Tilray Brands in the 2nd quarter worth approximately $939,000. Finally, Swiss National Bank boosted its stake in Tilray Brands by 4.4% in the 3rd quarter. Swiss National Bank now owns 2,013,038 shares of the company’s stock worth $3,483,000 after purchasing an additional 84,900 shares during the period. 9.35% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently issued reports on TLRY. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tilray Brands in a research report on Wednesday, January 21st. TD Cowen dropped their target price on shares of Tilray Brands from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Monday. Zacks Research raised shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 11th. Canaccord Genuity Group initiated coverage on shares of Tilray Brands in a report on Tuesday, January 27th. They issued a “hold” rating on the stock. Finally, Wall Street Zen upgraded shares of Tilray Brands from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Three equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $11.20.

Tilray Brands News Summary

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Roth upgraded Tilray to Buy after Q3 results, citing the company’s improving outlook and execution—this upgrade helped lift sentiment. Tilray rebounds as Roth Capital upgrades to Buy after Q3 results
• Positive Sentiment: Jefferies reiterated a Buy and kept a high $24 price target, highlighting strong cannabis sales and increased visibility into medium‑term results—this signals confidence from a major broker. Tilray Brands’ strong cannabis sales and upbeat outlook keeps Jefferies analysts bullish
• Positive Sentiment: Tilray reported record Q3 revenue (~$207M), 11% organic growth, gross profit expansion (~$55M) and a 73% jump in international cannabis revenue—management reaffirmed FY26 guidance, which supports the constructive narrative. Tilray Brands Delivers Record Q3 Fiscal 2026 Results
• Positive Sentiment: Sector tailwind: the FDA signaled it won’t enforce some CBD rules, which lifted cannabis/CBD names broadly and supports Tilray’s consumer-facing opportunity. Why Tilray and Other Cannabis Stocks Just Had Their Best Week of 2026
• Neutral Sentiment: Zacks and other analysts describe Q3 as mixed—revenue and narrowing losses are positives, but beverage weakness and margin pressure temper the bullish case. Should Tilray Brands Be in Your Portfolio Post Q3 Earnings?
• Neutral Sentiment: Analysis pieces note improving fundamentals but flag negative cash flow and execution/M&A risk—supportive for medium-term upside but caution on near-term volatility. Tilray Brands Is Looking Better
• Negative Sentiment: Tilray missed EPS expectations (loss of $0.24 vs. est. -$0.14), and investors have been wary of margin compression and beverage-segment softness—these factors triggered earlier intraday selling. Earnings and conference call details
• Negative Sentiment: Some analysts trimmed targets/ratings after the print: ATB Cormark cut its target to $9.00 (sector perform) and TD Cowen lowered expectations—mixed analyst action adds selling pressure at current levels. Analyst rating changes TD Cowen lowers expectations

Tilray Brands Stock Performance

NASDAQ TLRY opened at $6.55 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.81 and a quick ratio of 1.72. Tilray Brands, Inc. has a 1-year low of $3.51 and a 1-year high of $23.20. The business has a 50 day simple moving average of $7.32 and a two-hundred day simple moving average of $10.23. The stock has a market capitalization of $763.14 million, a PE ratio of -0.48 and a beta of 2.00.

Tilray Brands (NASDAQ:TLRY) last issued its quarterly earnings data on Wednesday, April 1st. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.10). The firm had revenue of $206.73 million for the quarter, compared to analysts’ expectations of $201.35 million. Tilray Brands had a negative return on equity of 3.31% and a negative net margin of 156.51%.During the same period last year, the company earned ($0.87) earnings per share. On average, research analysts predict that Tilray Brands, Inc. will post -0.2 EPS for the current fiscal year.

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.